Supernus Pharmaceuticals (SUPN)
Develops CNS medicines spanning ADHD, Parkinson’s disease, postpartum depression, and epilepsy.
Something off on this page? Send us feedback.
Develops and commercializes CNS medicines for ADHD, Parkinson’s disease, postpartum depression, epilepsy, and other movement disorders. Revenue comes primarily from U.S. product sales, with ZURZUVAE adding collaboration revenue through Biogen and the business operating as a single segment.
Develops and commercializes medicines for central nervous system disorders, with marketed products spanning ADHD, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Core brands include Qelbree, GOCOVRI, ZURZUVAE, ONAPGO, APOKYN, Oxtellar XR, Trokendi XR, XADAGO, and MYOBLOC.
Pairs drug-formulation and clinical-development capabilities with acquisitions and dedicated U.S. sales teams for ADHD, movement disorders, and postpartum depression. Revenue comes mainly from U.S. product sales; ZURZUVAE contributes collaboration revenue under a shared U.S. commercialization arrangement with Biogen.
Operates as one segment and outsources commercial manufacturing, while a concentrated wholesaler and distributor base accounts for most product revenue and specialty pharmacies carry several key brands. A pending all-stock merger with Indivior requires shareholder and regulatory approvals; the combined company is expected to retain the Supernus name and SUPN ticker.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Feb 25, 2026 | Craig-Hallum | Target | Target: — | Target: $65 |
| Dec 19, 2025 | Stifel Nicolaus | Target | Target: $38 | Target: $55 |
| Oct 9, 2025 | Piper Sandler | Upgrade | ||
| Oct 8, 2025 | Piper Sandler | Target | Target: $40 | Target: $65 |
| Sep 30, 2025 | Cantor Fitzgerald | Reiterate | Rating: —Target: $42 | Target: $63 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $372.1M · Total debt $40.2M · Total assets $1.43B · Shareholders' equity $1.03B
- Revenue
- $219.1M
- Operating income
- −$58.0M
- Net income
- −$58.4M
No dividends on record.
| Institutions | 104.93% | 60.99M shares | |
|---|---|---|---|
| 340 holders · as of Jun 30, 2026 | |||
| Insiders | 6.48% | 3.77M shares | |
| 9 holders · as of Aug 14, 2026 | |||
| Adds to | 111.41% | ||
58.13M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 111.41%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.09% | 9.35M | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 6.63% | 3.85M | as of Jun 30, 2026 |
Jack A. Khattar1Insiderdirector, officer: President, CEO | 5.97% | 2.75M | filed Aug 14, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.69% | 3.31M | as of Jun 30, 2026 |
Armistice Capital, LLCInstitution | 4.55% | 2.65M | as of Jun 30, 2026 |
- Jack A. Khattar's transaction reports restate only vehicles that traded; the 2019 ownership statement (2.75M) plus the 720.4K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 17, 2026 | Padmanabh P. Bhatt | officer: Sr. VP of IP, CSO | −50,000 | $50.30 |
| Mar 18, 2026 | Padmanabh P. Bhatt | officer: Sr. VP of IP, CSO | −7,250 | $49.60 |
| Mar 16, 2026 | Padmanabh P. Bhatt | officer: Sr. VP of IP, CSO | −50,000 | $50.28 |
| Mar 12, 2026 | Frederick M. Hudson | director | −5,369 | $50.61 |
| Mar 13, 2026 | Jack A. Khattar | director, officer: President, CEO | −35,000 | $50.37 |
- Takeda (ADR)
ADHD stimulant benchmark with Vyvanse and Shire-era scale
- AbbVie
Direct Parkinson's infusion rival through VYALEV and Duopa
- Johnson & Johnson
Concerta keeps a major stimulant alternative in ADHD
- Amneal Pharmaceuticals
Parkinson's specialty peer with CREXONT, RYTARY, and ONGENTYS
- Teva (ADR)
Generic ADHD and CNS pressure across branded franchises
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals | $43.58 | +1.87% | $2.48B | — | 15.1 | 3.0 | +32.4% |
| Takeda (ADR) | $18.92 | +0.13% | $60.11B | 52.5 | 59.7 | 2.0 | +4.2% |
| AbbVie | $263.49 | −0.37% | $467.37B | 74.5 | 17.3 | 7.3 | +10.2% |
| Johnson & Johnson | $267.28 | −0.81% | $649.40B | 31.2 | 22.5 | 6.6 | +6.6% |
| Amneal Pharmaceuticals | $19.53 | −3.13% | $6.44B | 41.4 | 19.6 | 2.1 | +9.9% |
| Teva (ADR) | $39.80 | −0.65% | $46.66B | 66.8 | 14.2 | 2.7 | −0.8% |
| Median | 52.5 | 19.6 | 2.7 | +6.6% |